Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424567 · ClinicalTrials.gov registry record · Phase 1
Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.
A Phase 1 study, sponsored by Vericel Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00424567: Clinical Trial Phase 1 study, sponsored by Vericel Corporation.
NCT00424567 is a Phase 1 study that was terminated before completion, run by Vericel Corporation. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00424567, a Phase 1 study, was terminated before completion, sponsored by Vericel Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this multi-center study is to obtain clinical data to substantiate that Aastrom TRC autologous bone marrow cells will regenerate bone in patients with established (appendicular skeletal) non union fractures, when used with one of the commonly employed commercially available allograft chip matrices.
Interventions
- PROCEDURE Fracture surgery
- DRUG Cultured Bone Marrow Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Why NCT00424567 stopped before completion
NCT00424567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Fracture surgery is the first listed.
NCT00424567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00424567 about?
NCT00424567 is a clinical study titled "Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.". The purpose of this multi-center study is to obtain clinical data to substantiate that Aastrom TRC autologous bone marrow cells will regenerate bone in patients with established (appendicular skeletal) non union fractures, when used with one of the commonly employed commercially available allograft ...
What is the current status of trial NCT00424567?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2003-10. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00424567?
The interventions under investigation include: Fracture surgery (PROCEDURE), Cultured Bone Marrow Tissue (DRUG).
Who is sponsoring clinical trial NCT00424567?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00424567's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia